|
Characteristic
|
Total (cases)
|
Small ENLN group [cases (%)]
|
Large ENLN group [cases (%)]
|
P valuea
|
|---|
|
Gender
| | | |
0.923
|
|
Male
|
194
|
66 (77.6)
|
128 (77.1)
| |
|
Female
|
57
|
19 (22.4)
|
38 (22.9)
| |
|
Age (years)
| | | |
0.661
|
|
<50
|
167
|
55 (64.7)
|
112 (67.5)
| |
|
≥50
|
84
|
30 (35.3)
|
54 (32.5)
| |
|
Smoking
| | | |
0.935
|
|
Yes
|
73
|
25 (29.4)
|
48 (28.9)
| |
|
No
|
178
|
60 (70.6)
|
118 (71.1)
| |
|
Drinking
| | | |
0.836
|
|
Yes
|
25
|
8 (9.4)
|
17 (10.2)
| |
|
No
|
226
|
77 (90.6)
|
149 (89.8)
| |
|
LDH (U/L)
| | | |
0.973
|
|
<245
|
242
|
82 (96.5)
|
160 (96.4)
| |
|
≥245
|
9
|
3 (3.5)
|
6 (3.6)
| |
|
Family history of cancer
| | | |
0.332
|
|
Yes
|
87
|
26 (30.6)
|
61 (36.7)
| |
|
No
|
164
|
59 (69.4)
|
105 (63.2)
| |
|
BED (Gy)
| | | |
0.821
|
|
<72
|
91
|
30 (35.3)
|
61 (36.7)
| |
|
≥72
|
160
|
55 (64.7)
|
105 (63.3)
| |
|
Chemotherapy
| | | |
0.222
|
|
Yes
|
152
|
47 (55.3)
|
105 (63.3)
| |
|
No
|
99
|
38 (44.7)
|
61 (36.7)
| |
|
T categoryb
| | | |
0.270
|
|
T1
|
80
|
27 (31.8)
|
53 (31.9)
| |
|
T2
|
54
|
24 (28.2)
|
30 (18.1)
| |
|
T3
|
87
|
25 (29.4)
|
62 (37.3)
| |
|
T4
|
30
|
9 (10.6)
|
21 (12.7)
| |
- The patients were divided into small and large ENLN groups using the cut-off value (5.5 mm) of the short diameter of the largest ENLN for the prediction of DFS
-
LDH lactate dehydrogenase, BED biological equivalent dose
-
a
P values were calculated using the Chi square test or Fisher’s exact test if indicated
-
bAccording to the 7th edition of the American Joint Committee on Cancer/Union for International Cancer Control (AJCC/UICC) staging system
